Webinar title:

Bispecific Antibody Discovery: Practical Strategies from MOA to Preclinical Candidates

Abstract:

Bispecific antibodies (BsAbs) enable diverse therapeutic MOAs such as retargeting cytotoxic effector cells, modulating receptor activity, and selectively recognizing pathogenic cells. However, advancing bsAbs from concept to preclinical candidates remains challenging, requiring comprehensive insights and technical expertise at every stage. 

This webinar will explore practical strategies for bsAb discovery, from lead identification and high-throughput (HTP) production to in vitro assays and in vivo studies. Through real-world case studies, we will highlight one-stop, modular solutions for bsAb design, screening, and functional characterization to support the development of next-generation bsAb therapeutics. 

In this webinar, you will learn:

• Advanced antibody discovery platforms for biology-driven lead identification 
• Innovative Quick ‘n’ Clean platform for HTP bsAb production, unlocking optimal pairings rapidly 
• Comprehensive in vitro functional assays across T-cell engagers (TCEs), immune checkpoint inhibitors, and autoimmune diseases 
• Extensive in vivo efficacy models and well-established PK/PD/Tox platforms delivering time- and cost-effective solutions

Speaker:

Macy Jin, MD, Director, CRO Services

Register Now

Webinar title:

In Vivo Pharmacology Maximizing Translational Relevance via NHP/Murine Models

Abstract:

In vivo pharmacology remains the gold standard for evaluating the efficacy and pharmacodynamics of therapeutic candidates in preclinical development. Selecting precise, clinically relevant animal models is critical for generating high-quality data and ensuring a seamless transition to clinical trials. This webinar will showcase our end-to-end, multi-species in vivo platform, leveraging NHP and murine models to support a comprehensive suite of PK/PD/Tox, efficacy, and histology assessments. Whether you’re developing mAbs, bsAbs, ADCs, or novel modalities, this session will equip you with practical insights to refine study design, mitigate risks, and streamline the path to clinical success.

In this webinar, you will learn:

• Rational study design to align preclinical models with human disease biology
• Key considerations for selecting optimal species and models that maximize translational relevance of PK/PD and efficacy
• Data interpretation to extract actionable insights from complex pharmacodynamic and histological datasets
• Proactive troubleshooting to overcome preclinical challenges and accelerate timelines

Speaker:

Zhili Yao, Ph.D., Director, CRO Services

View Recording

Webinar title:

Early-Stage Developability Assessment for Lead Optimization

Abstract:

Early-stage biologics discovery often prioritizes binding affinity but overlooks critical developability factors, leading to CMC and clinical challenges. This webinar introduces the Micro Developability platform, a high-throughput analytical suite that requires <1 mg of antibody per assay to assess key developability attributes like sequence liability, PK and stability. Through case studies, we will illustrate how these early assessments optimize leads, mitigate downstream risks, and facilitate a smooth transition to CMC.

You will gain valuable insight into:

• High-throughput assays with robust performance and high sensitivity for biophysical and PK profiling, including AC-SINS, BVP/DNA/insulin ELISA, FcRn affinity and serum stability
• Integrated developability assessments combining in silico modeling and in vitro assays to identify potential risks in early stage
• Micro-developability strategy for new modalities

Speaker:

Lei Guo, Ph.D. Director, CRO Services

View Recording

Webinar title:

Achieving High Titer & Superior Purity Across Diverse Bispecific Antibody Formats

Abstract:

Bispecific antibodies (BsAbs) are at the forefront of therapeutic innovation, but their production is often hindered by challenges such as low titers and difficult-to-remove impurities like homodimers and mispaired species. Additionally, each BsAb format presents unique complexities in the production process.

This webinar will showcase innovative solutions to these challenges, including ultra-high-titer CHO expression systems, optimized chain ratios, and Intact Mass-assisted purification processes tailored for various formats like CrossMab, WuXiBody, and others. Through detailed case studies, we will demonstrate how these approaches consistently achieve over 98% heterodimer purity and endotoxin levels below 0.1 EU/mg.

In this webinar, you will learn:

• Innovative strategies to overcome low titers, mispaired species and homodimers.
• Advanced chain ratio optimization for formats like CrossMab and WuXiBody, improving expression and titer.
• Case studies illustrating Intact Mass-assisted purification tailored for various formats, such as CrossMab, WuXiBody, and ScFv-Fab, consistently achieving heterodimer purity >98% and endotoxin levels <0.1 EU/mg.

Speaker:

Jiansheng Wu, Ph.D., Vice President, Head of CRO Services

View Recording

Webinar title:

Mass Spec Enables More Definitive Biologics Drug Discovery and Development

Abstract:

The inherent heterogeneity of protein therapeutics, resulting from structural modifications and sequence variants, presents significant challenges to their quality, efficacy and safety. Mass Spectrometry (Mass Spec) stands out as a pivotal tool, offering unparalleled sensitivity and specificity in elucidating protein primary structures and understanding structure-function relationships.

Join our webinar to explore WuXi Biologics’ advanced Mass Spec-based protein characterization, such as cIEF-MS, high throughput (HTP) Intact Mass, Mass Spec-based glycan platforms and de novo sequencing. Through detailed case studies, we will demonstrate how these innovative methodologies are accelerating the discovery and development of biologic drugs.

In this webinar, you will learn:

• Comprehensive approaches to Mass Spec-based protein characterization, tailored for biologics.
• Advanced Mass Spec techniques, including cIEF-MS for charge variants, HTP Intact Mass, glycan analysis, de novo sequencing, and more.
• How customized Mass Spec methods identify and resolve anomalies detected in routine testing like CE-SDS and icIEF.

Speakers:

Yongsheng Xiao, Ph.D., Senior Director, Protein Sciences

View Recording

Webinar title:

Optimizing Bispecific Antibody Production: From Identifying Optimal Pairings to Scale-up Processes

Abstract:

Join us for an insightful webinar where you will discover the latest advancements in bispecific antibody (bsAb) production, tailored to enhance your antibody drug discovery process. BsAb production continues to face challenges such as heterogeneity, production complexity, and stability issues, all of which can significantly affect the quality of the final product. In this webinar, our expert will introduce innovative strategies that range from high-throughput (HTP) small-scale screening of bsAb pairings to efficient and scalable production methods. Wet-lab case studies will demonstrate the successful application of these strategies, providing you with actionable insights.

In this webinar, you will learn:

• Innovative HTP platforms for rapid screening of optimal pairings.
• Scalable production technologies designed to streamline bsAb production.
• Advanced strategies to address the unique challenges of different bsAb formats.

Speaker:

Jiansheng Wu, Ph.D., Vice President, Protein Sciences

View Recording

Webinar title:

Innovative Production and Engineering Strategies for Fab, ScFv & VHH

Abstract:

Antibody fragments like Fab, ScFv, and VHH are emerging stars in antibody drug development, utilized both as standalone molecules and as building blocks of bispecific antibodies. However, their production and engineering face numerous challenges, including issues related to yield, purity, throughput, and stability. In this webinar, we will unveil innovative strategies to overcome these challenges, tailored to the distinctive characteristics of Fab, ScFv, and VHH. We’ll provide key insights into molecular design, high-titer CHO transient and stable pool production, and effective purification methods to accelerate your development of antibody fragments.

In this webinar, you will learn:

• Novel strategies to tackle common production challenges like low yields, throughput issues, and impurities in antibody fragment production.
• Advanced molecule engineering and linker design to mitigate aggregation and increase yield.
• Tailored approaches for optimizing the production of Fab, ScFv, and VHH, with a focus on specific strategies for each fragment type.

Speakers:

Jiansheng Wu, Ph.D., Vice President, Protein Sciences

View Recording

Webinar title:

Groundbreaking Innovations: High-Titer CHO Expression of Miniproteins & T-Cell-Related Proteins

Abstract:

As the demand for novel biologic drug modalities continues to rise, miniproteins and T-cell-related proteins are emerging as promising candidates. However, the production of these proteins for biologics development has posed numerous challenges. Join our upcoming webinar to explore two groundbreaking platforms that overcome common challenges and are revolutionizing the production of miniproteins and T-cell-related proteins, significantly accelerating biologics development.

In this webinar, you will learn:

• How the Miniprotein Line surpasses traditional E. coli methods, utilizing high-titer CHO system to enhance expression and achieve extra-low endotoxin levels.
• How the T-Cell Mate platform efficiently produces challenging T-cell-related proteins, including sTCR, TCR-Ab fusions and SCT, enabling high throughput and yields critical for advancing therapeutic proteins.
• Case studies demonstrating the successful use of these innovative platforms in producing high-purity miniproteins and T-cell-related proteins.

Speakers:

Jiansheng Wu, Ph.D., Vice President, Protein Sciences

View Recording

Webinar title:

Innovative Platforms for Rapid and Cost-Effective HTP Antibody & Protein Production

Abstract:

As the field of biologics development evolves rapidly, there is increasing demand for high-throughput (HTP) antibody and protein production that is fast and cost-effective. This webinar showcases two innovative HTP antibody and protein production platforms: Ultra 96 and 777. Both platforms are powered by our ultra-high titer transient CHO system and designed for fast, affordable production. The Ultra 96 platform, with its 96- and 24-DWP format, quickly produces hundreds to thousands of antibodies per run at 100-1,500 µg each. The 777 offers low endotoxin and aggregates antibody production at 1-100 mg scale. Each platform addresses challenges at different stages of drug discovery, accelerating your drug development journey.

In this webinar, you will learn:   

• How the Ultra 96 and 777 platforms combine speed, purity, and scalability to streamline the biologics discovery process.
• Strategies for efficient high-throughput antibody/protein production that align with current trends and demands in biologic drug development.
• Case studies that demonstrate the successful application of Ultra 96 and 777 platforms in producing a large number of biologics rapidly and cost-effectively.

Speakers:

Julia Su, Ph.D., Associate Director, Protein Sciences

View Recording

Webinar title:

Assessing Pharmacokinetics and Manufacturability in Early Biologics Drug Discovery Webinar

Abstract:

In the early stages of biologics drug discovery, it’s crucial to have assays that reliably correlate with human pharmacokinetics (PK) and manufacturability. In this webinar, we introduce our advanced high-throughput analytical suite, designed to assess critical developability parameters. This comprehensive approach incorporates both in silico tools and diverse in vitro assays, including AC-SINS, Baculovirus/DNA/insulin ELISA, FcRn binding, Serum stability and others. Our panel is formatted in a 96WP design and requires only ~100ug of sample per assay, making it particularly suitable for the early lead ID/lead op stages.

You will gain valuable insight into:   

• How an integrated suite of developability assays can help evaluate the suitability of biologics as potential drugs at an early stage
• How these micro developability tests use minimal material (<1 mg of protein) to allow lead molecules to be examined at an earlier stage.
• Case studies demonstrating how these  developability tests reliably correlate with human PK and manufacturability.

Speakers:

Han Yang, Assistant Director, Protein Sciences

View Recording

Webinar title:

Unlock the Optimal Pairings of Bispecific Antibody Through Small Scale HTP BsAb Production & Efficient Scale-up Strategies

Webinar Abstract:

Join us for an exclusive webinar where the groundbreaking strategies for the bispecific antibody production will be presented, transforming your antibody drug discovery efforts. Bispecific antibody production entails challenges like heterogeneity, production complexity, and stability issues, impacting the quality of the final product. In this webinar, our esteemed industry expert will introduce innovative strategies and solutions to address challenges, spanning from small-scale high-throughput screening of a vast number of bispecific antibody pairings to large-scale production. Real-world case studies will showcase the successful application of these strategies.

During the webinar, you will gain valuable insight into:

1. Novel strategies for optimizing the production of bispecific antibodies in drug development.
2. An innovative high throughput production platform to quickly screen the optimal pairings of bispecific antibody for accelerated discovery.
3. Cutting-edge technologies for large scale production of bispecific antibodies.

Speakers:

Jiansheng Wu, Ph.D., Head of BioDev Protein Sciences Department

View Recording